RxDoctor Payments Data

Angela Perry, MD

Ophthalmic Plastic and Reconstructive Surgery · Pasadena, CANPI 1063411858

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 80.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,937 and has fallen 97.8% since, to $132 in 2025.

$8,453in general payments, 2019–2025

Across 125 payments — averaging $67.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$7K
  • AbbVie$361
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$162
  • Tarsus Pharmaceuticals, Inc.$144
  • Mallinckrodt Hospital Products Inc.$143
  • Ocular Therapeutix, Inc.$131
  • plus $712 from 11 others

What the payments were for

  • Speaking & faculty fees$4,00047%
  • Travel & lodging$1,05212%
  • Food & beverage$3,40140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,453 in reported general payments places this provider in the 75th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.

See all ophthalmic plastic and reconstructive surgery providers in California

Medicare billing

Part B allowed, 2024
$16,063
Medicare patients
49
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$11,807
ErythromycinErythromycin Base436$4,839
MoxifloxacinMoxifloxacin Hcl86$2,301
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha89$847
Ciprofloxacin Hcl65$701
Methylprednisolone105$626
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$595
Neomycin-Bacitracin-PolymyxinNeomycin/Bacitracin/Polymyxinb25$586
Prednisolone Acetate14$579
Doxycycline Hyclate17$414
Latanoprost25$358
Timolol Maleate15$219
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$135
Cephalexin13$104
Clindamycin Hcl12$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$361$11,80721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.

Other ophthalmic plastic and reconstructive surgery in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →